Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKAN Akanda	$3.68 -8.8%	$4.03	$2.91 ▼ $8.75	$1.70M	1.59	53,038 shs	39,605 shs
RLYB Rallybio	$0.54 -4.3%	$0.47	$0.22 ▼ $1.24	$22.40M	-1.12	1.17 million shs	194,156 shs
SONN Sonnet BioTherapeutics	$3.26 -3.6%	$3.81	$1.08 ▼ $19.30	$22.12M	1.04	1.58 million shs	328,973 shs
TAOX Synaptogenix	$5.73 -12.5%	$0.00	$1.84 ▼ $11.98	$20.00M	1.87	423,486 shs	403,130 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKAN Akanda	+2.81%	-1.56%	-7.22%	+6.93%	-44.41%
RLYB Rallybio	-5.00%	-5.69%	+19.14%	+78.52%	-51.71%
SONN Sonnet BioTherapeutics	-4.79%	0.00%	+3.68%	+187.66%	-41.92%
TAOX Synaptogenix	-5.35%	+1.55%	-4.52%	+654,999,900.00%	+654,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKAN Akanda	0.852 of 5 stars	0.0	3.0	0.0	0.0	2.3	1.7	0.6
RLYB Rallybio	2.993 of 5 stars	3.0	4.0	0.0	0.0	2.7	1.7	1.3
SONN Sonnet BioTherapeutics	3.4898 of 5 stars	3.5	4.0	0.0	0.0	3.0	0.0	0.0
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKAN Akanda	0.00	N/A	N/A	N/A
RLYB Rallybio	2.00	Hold	$5.00	832.84% Upside
SONN Sonnet BioTherapeutics	3.00	Buy	$20.00	513.50% Upside
TAOX Synaptogenix	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKAN Akanda	$840K	2.01	N/A	N/A	$9.37 per share	0.39
RLYB Rallybio	$640K	35.00	N/A	N/A	$1.10 per share	0.49
SONN Sonnet BioTherapeutics	$1M	22.02	N/A	N/A	($0.45) per share	-7.24
TAOX Synaptogenix	N/A	N/A	N/A	N/A	$4.95 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKAN Akanda	-$4.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	-$57.78M	-$0.94	N/A	N/A	N/A	-5,473.33%	-71.66%	-65.06%	11/6/2025 (Estimated)
SONN Sonnet BioTherapeutics	-$7.44M	N/A	0.00	∞	N/A	N/A	-4,646.10%	-342.21%	N/A
TAOX Synaptogenix	-$12.77M	-$20.16	N/A	∞	N/A	N/A	-277.76%	-150.79%	N/A

Latest AKAN, RLYB, SONN, and TAOX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/15/2025	Q2 2025	TAOX Synaptogenix	N/A	-$11.26	N/A	-$11.26	N/A	N/A
8/13/2025	Q3 2025	SONN Sonnet BioTherapeutics	-$0.49	-$0.95	-$0.46	-$0.95	N/A	N/A
8/7/2025	Q2 2025	RLYB Rallybio	-$0.2450	-$0.22	+$0.0250	-$0.22	N/A	$0.21 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKAN Akanda	N/A	N/A	N/A	N/A	N/A
RLYB Rallybio	N/A	N/A	N/A	N/A	N/A
SONN Sonnet BioTherapeutics	N/A	N/A	N/A	N/A	N/A
TAOX Synaptogenix	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKAN Akanda	N/A	1.39	1.39
RLYB Rallybio	N/A	9.98	9.98
SONN Sonnet BioTherapeutics	N/A	0.26	0.26
TAOX Synaptogenix	N/A	20.52	20.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKAN Akanda	1.00%
RLYB Rallybio	90.34%
SONN Sonnet BioTherapeutics	9.45%
TAOX Synaptogenix	10.34%

Insider Ownership

Company	Insider Ownership
AKAN Akanda	20.39%
RLYB Rallybio	8.70%
SONN Sonnet BioTherapeutics	2.00%
TAOX Synaptogenix	2.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKAN Akanda	110	460,000	364,000	Not Optionable
RLYB Rallybio	40	41.79 million	38.15 million	Not Optionable
SONN Sonnet BioTherapeutics	10	6.75 million	6.62 million	Not Optionable
TAOX Synaptogenix	4	3.49 million	3.39 million	N/A

AKAN, RLYB, SONN, and TAOX Headlines

Recent News About These Companies

Wall Street Zen Downgrades Synaptogenix (NASDAQ:TAOX) to Sell

August 19, 2025 | americanbankingnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKAN, RLYB, SONN, and TAOX Company Descriptions

Akanda NASDAQ:AKAN

$3.68 -0.36 (-8.81%)

As of 03:53 PM Eastern

Akanda Corp., through its subsidiaries, engages in the cultivation, manufacture, and distribution of cannabis products to patients worldwide. It offers medicinal-grade cannabis and cannabis based medical and wellness products. The company was incorporated in 2021 and is headquartered in New Romney, the United Kingdom.

Rallybio NASDAQ:RLYB

$0.54 -0.02 (-4.32%)

As of 03:53 PM Eastern

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Sonnet BioTherapeutics NASDAQ:SONN

$3.26 -0.12 (-3.55%)

As of 03:53 PM Eastern

Sonnet BioTherapeutics Holdings, Inc., a biotechnology company, owns a platform for biologic medicines of single or bifunctional action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead product candidate is SON-1010, a fully human single-chain version of interleukin 12 that is in Phase 1b/2a clinical trial for the treatment of solid tumor indications, including ovarian cancer, non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6, which is in Phase 1b/I2a clinical trail to treat chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy; and SON-1210, a bispecific compound for solid tumor indications, including colorectal cancer. It has a license agreement with New Life Therapeutics Pte, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin-6; and strategic development collaboration with Sarcoma Oncology Center to advance SON-1210. The company is headquartered in Princeton, New Jersey.

Synaptogenix NASDAQ:TAOX

$5.73 -0.82 (-12.52%)

As of 03:33 PM Eastern

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time